Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B

Journal of Viral Hepatitis

Volumn 18, Issue 7, 2011, Pages

  Mirandola, S ^a,b   Campagnolo, D ^a   Bortoletto, G ^a   Franceschini, L ^a   Marcolongo, M ^a,b   Alberti, A ^a,b  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

genotype; hepatitis B virus; mutation; nucleos(t)ide analogue n ve; resistance

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC HEPATITIS; DISEASE ASSOCIATION; DNA EXTRACTION; DNA HYBRIDIZATION; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; STRUCTURAL GENE; VIRUS LOAD; VIRUS MUTATION;

EID: 79959577813     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01435.x     Document Type: Article

References (41)

1. EASL International Consensus Conference on Hepatitis B. Consensus statement. J Hepatol 2003; 38: 533-540.
2. Fattovich G, Bortolotti F, Donato F,. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48 (2): 335-352.
3. Ghany MG, Doo EC,. Assessment and management of chronic hepatitis B. Infect Dis Clin North Am 2006; 20 (1): 63-79. (Pubitemid 43343734)
4. Holomán J, Glasa J,. EASL clinical practice guidelines. J Hepatol 2009; 51 (4): 821-822.
5. Carosi G, Rizzetto M,. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis 2008; 40 (8): 603-617.
6. Dienstag JL,. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
7. Zoulim F, Locarnini S,. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137 (5): 1593-1608.e1-2.
8. Zoulim F, Buti M, Lok AS,. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat 2007; 14 (Suppl 1): 29-36. Review. (Pubitemid 47624112)
9. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46 (1): 254-265. Review. (Pubitemid 47171942)
10. Ghany MG, Doo EC,. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49 (5 Suppl): S174-S184.
11. Ghany M, Liang TJ,. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007; 132 (4): 1574-1585. Review. (Pubitemid 46627588)
12. Colonno RJ, Rose RE, Pokornowski K,. Four year assessment of entecavir resistance in nucleoside-naıÂve and lamivudine refractory patients [Abstract]. J Hepatol 2007; 46 (Suppl 1): S294.
13. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51 (3): 902-911. (Pubitemid 46355274)
14. Karino Y, Toyota J, Kumada H, et al. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int 2010; 4 (1): 414-422.
15. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009; 50 (4): 1064-1071.
16. Min XC, Miao XH, Zhao SM, Zhao KK, Yang DG,. [The spontaneous YMDD mutation rate in chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi 2009; 17 (12): 887-890. Chinese.
17. Masaadeh HA, Hayajneh WA, Alqudah EA,. Hepatitis B virus genotypes and lamivudine resistance mutations in Jordan. World J Gastroenterol 2008; 14 (47): 7231-7234.
18. Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM,. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine. Int J Infect Dis 2008; 12 (1): 83-87. (Pubitemid 350299229)
19. Akarsu M, Sengonul A, Tankurt E, et al. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol 2006; 21 (12): 1783-1788. (Pubitemid 44656997)
20. Shi M, Yang ZJ, Wang RS, et al. Rapid quantitation of lamivudine-resistant mutants in lamivudine treated and untreated patients with chronic hepatitis B virus infection. Clin Chim Acta 2006; 373 (1-2): 172-175. (Pubitemid 44308544)
21. Huang ZM, Huang QW, Qin YQ, et al. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 2005; 11 (6): 867-870.
22. Heo J, Cho M, Kim HH, et al. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci 2004; 19 (4): 541-546. (Pubitemid 39194218)
23. Kobayashi S, Ide T, Sata M,. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001; 34 (4): 584-586. (Pubitemid 32328516)
24. Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002; 37 (2): 259-265. (Pubitemid 34833089)
25. Pastor R, Habersetzer F, Fafi-Kremer S, et al. Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naîve patients. World J Gastroenterol 2009; 15 (6): 753-755.
26. Pollicino T, Isgrà G, Di Stefano R, et al. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. Antivir Ther 2009; 14 (5): 649-654.
27. Han Y, Huang LH, Liu CM, et al. Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naîve patients. J Gastroenterol Hepatol 2009; 24 (8): 1417-1423.
28. Margeridon-Thermet S, Shulman NS, Ahmed A, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI- naîve patients. J Infect Dis 2009; 199 (9): 1275-1285.
29. Guo JJ, Li QL, Shi XF, et al. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naîve patient. Antiviral Res 2009; 81 (2): 180-183.Epub 2008 Oct 21.
30. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354 (17): 1807-1812.
31. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H,. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93 (9): 4398-4402. (Pubitemid 26144299)
32. Günther S, Fischer L, Pult I, Sterneck M, Will H,. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52: 25-137.
33. Girones R, Miller RH,. Mutation rate of the hepadnavirus genome. Virology 1989; 170: 595-597. (Pubitemid 19162574)
34. Sheldon J, Soriano V,. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008; 61 (4): 766-768.Epub 2008 Jan 24. Review. (Pubitemid 351426057)
35. Sheldon J, RodÃs B, Zoulim F, Bartholomeusz A, Soriano V,. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 2006; 13 (7): 427-434. Review.
36. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293 (2): 305-313.
37. Torresi J,. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25 (2): 97-106. Review. (Pubitemid 35287234)
38. Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS,. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 2008; 13 (3): 439-447. (Pubitemid 352016737)
39. Borroto-Esoda K, Miller MD, Arterburn S,. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 2007; 47 (4): 492-498. (Pubitemid 47334760)
40. Curtis M, Zhu Y, Borroto-Esoda K,. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J Infect Dis 2007; 196 (10): 1483-1486. (Pubitemid 351411984)
41. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS,. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48 (3): 391-398.